Peripheral serotonin in alzheimer’s disease

Adarsh M. Kumar; Steven Sevush; Mahendra Kumar; Julio Ruiz; Carl Eisdorfer

doi:10.1159/000119205

Peripheral serotonin in alzheimer’s disease

Adarsh M. Kumar, Steven Sevush, Mahendra Kumar, Julio Ruiz, Carl Eisdorfer

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

The platelet has been suggested to be a peripheral model of the central serotonergic neuron. This investigation was carried out in order to test the hypothesis that levels of serotonin (5-HT) in the platelet will be decreased in Alzheimer's disease (AD) since neurochemical studies suggest that levels of 5-HT are decreased in the brain of AD patients. We investigated platelet and plasma 5-HT in a group of AD patients (n = 22) as well as in age-matched normal control subjects (n = 20). The results show that the platelet level of 5-HT was significantly reduced in AD (65.7 ± 28.41 ng/10⁸ platelets in AD vs. 112.9 ± 35.11 ng/10⁸ platelets in controls; p = 0.0001). There was no effect on the levels of its metabolite 5-hydroxyindoleacetic acid. These findings suggest that the peripheral serotonergic system in AD is adversely affected.

Original language	English (US)
Pages (from-to)	9-12
Number of pages	4
Journal	Neuropsychobiology
Volume	32
Issue number	1
DOIs	https://doi.org/10.1159/000119205
State	Published - 1995
Externally published	Yes

Keywords

Alzheimer's disease
Platelet
Serotonin

ASJC Scopus subject areas

Psychiatry and Mental health
Neuroscience(all)
Psychology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000119205

Cite this

@article{6618fe5290f14a3a976cb11a789539fe,

title = "Peripheral serotonin in alzheimer{\textquoteright}s disease",

abstract = "The platelet has been suggested to be a peripheral model of the central serotonergic neuron. This investigation was carried out in order to test the hypothesis that levels of serotonin (5-HT) in the platelet will be decreased in Alzheimer's disease (AD) since neurochemical studies suggest that levels of 5-HT are decreased in the brain of AD patients. We investigated platelet and plasma 5-HT in a group of AD patients (n = 22) as well as in age-matched normal control subjects (n = 20). The results show that the platelet level of 5-HT was significantly reduced in AD (65.7 ± 28.41 ng/108 platelets in AD vs. 112.9 ± 35.11 ng/108 platelets in controls; p = 0.0001). There was no effect on the levels of its metabolite 5-hydroxyindoleacetic acid. These findings suggest that the peripheral serotonergic system in AD is adversely affected.",

keywords = "Alzheimer's disease, Platelet, Serotonin",

author = "Kumar, {Adarsh M.} and Steven Sevush and Mahendra Kumar and Julio Ruiz and Carl Eisdorfer",

year = "1995",

doi = "10.1159/000119205",

language = "English (US)",

volume = "32",

pages = "9--12",

journal = "International Pharmacopsychiatry",

issn = "0302-282X",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Peripheral serotonin in alzheimer’s disease

AU - Kumar, Adarsh M.

AU - Sevush, Steven

AU - Kumar, Mahendra

AU - Ruiz, Julio

AU - Eisdorfer, Carl

PY - 1995

Y1 - 1995

N2 - The platelet has been suggested to be a peripheral model of the central serotonergic neuron. This investigation was carried out in order to test the hypothesis that levels of serotonin (5-HT) in the platelet will be decreased in Alzheimer's disease (AD) since neurochemical studies suggest that levels of 5-HT are decreased in the brain of AD patients. We investigated platelet and plasma 5-HT in a group of AD patients (n = 22) as well as in age-matched normal control subjects (n = 20). The results show that the platelet level of 5-HT was significantly reduced in AD (65.7 ± 28.41 ng/108 platelets in AD vs. 112.9 ± 35.11 ng/108 platelets in controls; p = 0.0001). There was no effect on the levels of its metabolite 5-hydroxyindoleacetic acid. These findings suggest that the peripheral serotonergic system in AD is adversely affected.

AB - The platelet has been suggested to be a peripheral model of the central serotonergic neuron. This investigation was carried out in order to test the hypothesis that levels of serotonin (5-HT) in the platelet will be decreased in Alzheimer's disease (AD) since neurochemical studies suggest that levels of 5-HT are decreased in the brain of AD patients. We investigated platelet and plasma 5-HT in a group of AD patients (n = 22) as well as in age-matched normal control subjects (n = 20). The results show that the platelet level of 5-HT was significantly reduced in AD (65.7 ± 28.41 ng/108 platelets in AD vs. 112.9 ± 35.11 ng/108 platelets in controls; p = 0.0001). There was no effect on the levels of its metabolite 5-hydroxyindoleacetic acid. These findings suggest that the peripheral serotonergic system in AD is adversely affected.

KW - Alzheimer's disease

KW - Platelet

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0028989991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028989991&partnerID=8YFLogxK

U2 - 10.1159/000119205

DO - 10.1159/000119205

M3 - Article

C2 - 7566524

AN - SCOPUS:0028989991

VL - 32

SP - 9

EP - 12

JO - International Pharmacopsychiatry

JF - International Pharmacopsychiatry

SN - 0302-282X

IS - 1

ER -

Peripheral serotonin in alzheimer’s disease

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this